OrganiGram Holdings Inc
Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Boxhot, Ediso… Read more
OrganiGram Holdings Inc (OGI) - Net Assets
Latest net assets as of December 2025: $369.15 Million USD
Based on the latest financial reports, OrganiGram Holdings Inc (OGI) has net assets worth $369.15 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($530.24 Million) and total liabilities ($161.09 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $369.15 Million |
| % of Total Assets | 69.62% |
| Annual Growth Rate | 66.51% |
| 5-Year Change | -27.24% |
| 10-Year Change | 688.81% |
| Growth Volatility | 8503.96 |
OrganiGram Holdings Inc - Net Assets Trend (2012–2025)
This chart illustrates how OrganiGram Holdings Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for OrganiGram Holdings Inc (2012–2025)
The table below shows the annual net assets of OrganiGram Holdings Inc from 2012 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $349.13 Million | +14.10% |
| 2024-09-30 | $305.99 Million | +12.65% |
| 2023-09-30 | $271.62 Million | -46.54% |
| 2022-09-30 | $508.06 Million | +5.89% |
| 2021-09-30 | $479.81 Million | +60.19% |
| 2020-09-30 | $299.53 Million | -8.40% |
| 2019-09-30 | $327.01 Million | +77.15% |
| 2018-09-30 | $184.59 Million | +122.32% |
| 2017-09-30 | $83.03 Million | +87.60% |
| 2016-09-30 | $44.26 Million | +463.53% |
| 2015-09-30 | $7.85 Million | +31964.23% |
| 2014-09-30 | $24.50K | -90.71% |
| 2013-09-30 | $263.80K | -42.88% |
| 2012-09-30 | $461.87K | -- |
Equity Component Analysis
This analysis shows how different components contribute to OrganiGram Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 60850842400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $919.91 Million | 263.49% |
| Other Comprehensive Income | $37.95 Million | 10.87% |
| Total Equity | $349.13 Million | 100.00% |
OrganiGram Holdings Inc Competitors by Market Cap
The table below lists competitors of OrganiGram Holdings Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NervGen Pharma Corp
OTCQB:NGENF
|
$135.47 Million |
|
UNISEM Co. Ltd
KQ:036200
|
$135.48 Million |
|
Richardson Electronics Ltd
NASDAQ:RELL
|
$135.48 Million |
|
Zhejiang Meishuo Electric Technology Co. Ltd. A
SHE:301295
|
$135.48 Million |
|
Open Orphan plc
PINK:OPORF
|
$135.41 Million |
|
Vinte Viviendas Integrales S.A.B. de C.V
MX:VINTE
|
$135.41 Million |
|
Global Standard Technology Limited
KQ:083450
|
$135.39 Million |
|
Avita Medical Ltd
NASDAQ:RCEL
|
$135.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OrganiGram Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 305,989,000 to 349,130,000, a change of 43,141,000 (14.1%).
- Net loss of 17,776,962 reduced equity.
- New share issuances of 41,181,000 increased equity.
- Other comprehensive income increased equity by 883,000.
- Other factors increased equity by 18,853,962.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-17.78 Million | -5.09% |
| Share Issuances | $41.18 Million | +11.8% |
| Other Comprehensive Income | $883.00K | +0.25% |
| Other Changes | $18.85 Million | +5.4% |
| Total Change | $- | 14.10% |
Book Value vs Market Value Analysis
This analysis compares OrganiGram Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.52x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 5.41x to 0.52x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-09-30 | $0.26 | $1.43 | x |
| 2013-09-30 | $0.13 | $1.43 | x |
| 2014-09-30 | $0.01 | $1.43 | x |
| 2015-09-30 | $0.60 | $1.43 | x |
| 2016-09-30 | $3.02 | $1.43 | x |
| 2017-09-30 | $3.42 | $1.43 | x |
| 2018-09-30 | $5.82 | $1.43 | x |
| 2019-09-30 | $9.28 | $1.43 | x |
| 2020-09-30 | $6.94 | $1.43 | x |
| 2021-09-30 | $7.49 | $1.43 | x |
| 2022-09-30 | $5.96 | $1.43 | x |
| 2023-09-30 | $3.34 | $1.43 | x |
| 2024-09-30 | $3.21 | $1.43 | x |
| 2025-09-30 | $2.73 | $1.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently OrganiGram Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -9.55%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.61x
- Recent ROE (-5.09%) is above the historical average (-96.25%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -30.35% | 0.00% | 0.00x | 1.09x | $-186.35K |
| 2013 | -142.24% | 0.00% | 0.00x | 1.28x | $-401.63K |
| 2014 | -975.71% | -294.72% | 0.58x | 5.71x | $-241.45K |
| 2015 | -16.26% | -129.42% | 0.07x | 1.80x | $-2.06 Million |
| 2016 | 1.91% | 13.82% | 0.11x | 1.22x | $-3.58 Million |
| 2017 | -13.12% | -202.08% | 0.06x | 1.12x | $-19.19 Million |
| 2018 | 11.11% | 165.04% | 0.04x | 1.64x | $2.05 Million |
| 2019 | -2.92% | -11.87% | 0.19x | 1.31x | $-42.24 Million |
| 2020 | -45.46% | -156.87% | 0.21x | 1.39x | $-166.11 Million |
| 2021 | -27.24% | -165.11% | 0.14x | 1.15x | $-178.68 Million |
| 2022 | -2.81% | -9.80% | 0.25x | 1.14x | $-65.09 Million |
| 2023 | -84.48% | -153.80% | 0.50x | 1.10x | $-256.64 Million |
| 2024 | -14.85% | -28.43% | 0.39x | 1.33x | $-76.04 Million |
| 2025 | -5.09% | -9.55% | 0.33x | 1.61x | $-52.69 Million |
Industry Comparison
This section compares OrganiGram Holdings Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OrganiGram Holdings Inc (OGI) | $369.15 Million | -30.35% | 0.44x | $135.42 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |